Elicio Therapeutics (ELTX) Equity Average (2020 - 2026)

Elicio Therapeutics (ELTX) has 7 years of Equity Average data on file, last reported at $99500.0 in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 108.26% year-over-year to $99500.0; the trailing twelve-month figure through Mar 2026 stood at $99500.0 (up 108.26% YoY), and the FY2025 full-year result was -$4.8 million, down 15962.3% from the prior year.
• Equity Average for Q1 2026 stood at $99500.0, down from $2.7 million in the prior quarter.
• Across five years, Equity Average topped out at $18.4 million in Q3 2023 and bottomed at -$106.0 million in Q1 2023.
• The 5-year median for Equity Average is -$1.2 million (2025), against an average of -$28.1 million.
• The widest annual swing landed in 2022, when Equity Average plunged 7922.07%; it then surged 233.69% in 2025.
• A 5-year view of Equity Average shows it stood at -$98.9 million in 2022, then soared by 112.46% to $12.3 million in 2023, then tumbled by 222.87% to -$15.1 million in 2024, then soared by 117.99% to $2.7 million in 2025, then sank by 96.35% to $99500.0 in 2026.
• The last three Equity Average figures came in at $99500.0 (Q1 2026), $2.7 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.

Peer Comparison